Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423201 · ClinicalTrials.gov registry record
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 262
- Enrollment target
NCT01423201: Completed study, sponsored by Stanford University.
NCT01423201 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 262 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423201 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 262 participants
- Enrollment target
Study Summary
Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect. TIA diagnosis can be challenging and an expert stroke evaluation combined with magnetic resonance imaging (MRI) could improve the diagnosis accuracy. The risk of a debilitating stroke can be as high as 5% during the first 72 hrs after TIA. TIA characteristics (duration, type of symptoms, age of the patient), the presence of a significant narrowing of the neck vessels responsible for the patient's symptoms (symptomatic stenosis), and an abnormal MRI are associated with an increased risk of stroke. An emergent evaluation and treatment of TIA patients by a stroke specialist could reduce the risk of stroke to 2%. Stanford has implemented an expedited triage pathway for TIA patients combining a clinical evaluation by a stroke neurologist, an acute MRI of the brain and the vessels and a sampling of biomarkers (Lp-PLA2). The investigators are investigating the yield of this unique approach to improve TIA diagnosis, prognosis and secondary stroke prevention. The objective of this prospective cohort study is to determine which factors will help the physician to confirm the diagnosis of TIA and to define the risk of stroke after a TIA.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-11-02 |
What the finished NCT01423201 record still lists
NCT01423201 is an observational study that tracks outcomes without assigning an intervention. The registered 262 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01423201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01423201 about?
NCT01423201 is a clinical study titled "Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk". Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect. TIA diagnosis can be challenging and an expert stroke evaluation combined with magnetic resonance imagi...
What is the current status of trial NCT01423201?
This trial is currently completed. The enrollment target is 262 participants. The study started on 2010-09. Estimated completion is 2017-11-02.
Who is sponsoring clinical trial NCT01423201?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
- NCT06780137 · 262 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia